

MICROMEDEX NATIONAL DRUG FILES UK DRUG FILE



How to save pharmacists' precious time, cross-referencing numerous sources of information ...

A question of trust in the evidence at hand when making critical patient safety decisions ...

Difficult choices about which drug information resources to keep as the NHS faces further cuts ...

MICROMEDEX HAS THE ANSWER.

A SINGLE RESOURCE FOR DETAILED EVIDENCE AND UK-APPROVED DRUG INFORMATION.

For more than 30 years, over 3,500 hospitals and healthcare institutions in 85 countries have trusted Micromedex. Now there's no need to go anywhere else to find UK SmPCs and information about medicines licensed for use in the UK — side-by-side with the comprehensive evidence you've always relied upon. The new UK Drug File delivers UK-approved dose, use, and possible side-effects information, in the familiar, consistent Micromedex format.

NO GAPS, NO INCONSISTENCIES. JUST CLEAR EVIDENCE AND FAST ANSWERS.

In-house editorial staff ensures quality and consistency

An ongoing review of the world's medical journals by our editorial team of 90+ healthcare professionals — physicians, clinical pharmacists, medical librarians, and an expert in research methodology — includes evaluation and synthesis of more than half a million articles annually to provide appropriate treatment recommendations. We scrutinize the full body of evidence so you can be confident your decisions are based on the most complete, relevant, and consistent information available.

Beyond drug summaries and package insert data to deliver full evidence

You'll find unparalleled coverage of off-label drug use, mechanism of action, how side effects work in certain conditions, in-trial results, therapeutic use, and comparative data. Unlike other resources, Micromedex consistently provides in-line referencing and fully cited studies so you always have the complete picture. There's no need to search multiple levels of content because our summary and in-depth content is linked, clinically consistent and accessible from a single screen.

Evidence ratings and recommendations take you closer to the answer

Even for those complex, out-of-the-ordinary questions, we give you the context behind the evidence. We cover unique or controversial issues surrounding the drug or treatment. You'll find no inconsistencies and no need to waste time reconciling conflicting information. Simple icons, unique evidence ratings and actionable recommendations help you make the critical decisions. Fast.

NOW WITH MICROMEDEX YOU CAN:

- Consult the eMC's Summary of Product Characteristics
- Search on generic or trade names for dose and form
- View indications approved by the MHRA and EMA
- Save time with the information you need all in one place

THE COMPLETE PICTURE:

- Literature surveillance and evaluation by in-house editorial staff
- Complete, cited evidence to support off-label use decisions
- In-line referencing of the full body of evidence
- Strength of evidence and efficacy ratings; actionable recommendations
- More than just a drug summary or package insert
- The whole picture on which to make confident decisions

Available Routes ▾

Acetaminophen

Acetaminophen (Paracetamol) [contained in: Panadol]

Intravenous, Oral, Rectal
360° View Dashboard

MICROMEDEX DRUG

- Adult Dosing
- Pediatric Dosing
- FDA-Labelled Ind
- Non-FDA Labelled
- Contraindications

View summary document

OTHER INFORMATION

MARTINDALE

- Paracetamol

UNITED KINGDOM - DATAPHARM (nnn RESULTS)

- Avedon Suppositories 60, 125, 250 mg
- Anadin Paracetamol Tablets
- Boots Cold & Flu Relief Powders Lemon Flavor
- Boots Pain Relief 3 Months Plus Paracetamol 120mg/5ml Suspension
- Boots Pain Relief Paracetamol 120mg/5ml Suspension
- Boots Pain Relief Paracetamol Suspension 3 Months Plus
- Boots Paracetamol 500 mg Tablets
- Boots Paracetamol 500mg Caplets
- Boots Paracetamol 500mg Capsules
- Boots Paracetamol 500mg Capsules (GSL)
- Boots Paracetamol 500mg Capsules (P)
- Boots Paracetamol Pain Relief 3 Years + 250mg/5ml Suspension Strawberry Flavour
- Boots Paracetamol Soluble 500mg Tablets
- Boots Strawberry Pain Relief 3 Months Plus Paracetamol 120mg/5ml Suspension or Almus Paracetamol

PRINT CLOSE

PDRB:

- Tylenol 8 Hour Extended Release Caplets
- Concentrated Tylenol Infants' Drops

CONSUMER DRUG INFO

- ACETAMINOPHEN (Intravenous route) - a-seet-a-MH-oh-fen
- ACETAMINOPHEN (Oral route)

ACETAMINOPHEN/Dichloroacetophenone/somebiphen Mucosa

ACETAMINOPHEN/Hydrocodone Bitartrate

MORE >

MARTINDALE - OTHER INFO (1 result)



THOMSON REUTERS™

**CAN YOUR DRUG INFORMATION RESOURCES ANSWER ALL THESE QUESTIONS?
MICROMEDEX CAN.**

- What's the licensed dose for this medicine here in the UK?
- What are the MHRA-approved indications for this therapy?
- What are the alternative forms for this drug?
- How should I prescribe this medicine?

“With Micromedex, I'm sure to find what I'm looking for.”

MICROMEDEX® 2.0 | 1.0 | MOBILE MY SUBSCRIPTION | MICROMEDEX GATEWAY | LOG OUT | HELP

Tools: Drug Interactions | Trisfel's™2 IV Compatibility | Drug Identification | Tox & Drug Product Lookup | Drug Comparison | RED BOOK Online® | Calculators | Formulary | CareNotes® | NeoFax®

Enter one or more search terms **SEARCH** Example Searches

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
4.3 CONTRAINDICATIONS
4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
4.5 INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION
4.6 PREGNANCY AND LACTATION
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
4.8 UNDESIRABLE EFFECTS
4.9 OVERDOSE

Panadol Capsules Print
United Kingdom Drug Information Expand All Collapse All Top of Page

1. NAME OF THE MEDICINAL PRODUCT
• Panadol / Paracetamol Capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
• Each capsule contains Paracetamol Ph Eur 500.0 mg

3. PHARMACEUTICAL FORM

- How well would this drug therapy work for my patient, under these specific conditions?
- How strong is the evidence supporting use of this medicine in this way?
- What is the longest duration of this dose used in clinical trials?
- Is putting my patient on this regimen worth the risk of the side effects?
- How many patients were in this study, and were they similar to my patient?
- What was the clinical significance of the effects of this drug?

ABOUT THOMSON REUTERS

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.

thomsonreuters.com

Thomson Reuters
777 E. Eisenhower Parkway
Ann Arbor, MI 48108 USA
Phone +1 877 843 6796

MICROMEDEX® 2.0 | 1.0 | MOBILE MY SUBSCRIPTION | MICROMEDEX GATEWAY | LOG OUT | HELP

Tools: Drug Interactions | Trisfel's™2 IV Compatibility | Drug Identification | Tox & Drug Product Lookup | Drug Comparison | RED BOOK Online® | Calculators | Formulary | CareNotes® | NeoFax®

Enter one or more search terms **SEARCH** Example Searches

OVERVIEW
DOSING INFORMATION
Drug Properties
Storage and Stability
Adult Dosage
Pediatric Dosage
PHARMACOKINETICS
Onset and Duration
Drug Concentration Levels
ADME
CAUTIONS
Black Box Warning
Contraindications
Precautions
Adverse Reactions
Teratogenicity/Effects in Pregnancy/Breastfeeding
CLINICAL APPLICATIONS
Monitoring Parameters
Patient Instructions
Place In Therapy
Mechanism of Action / Pharmacology
Therapeutic Uses
Comparative Efficacy / Evaluation With Other Therapies
REFERENCES

BEVACIZUMAB Display Entire Document Print
DRUGDEX® Evaluations OTHER SOURCES Expand All Collapse All Top of Page

CLINICAL APPLICATIONS
Age related macular degeneration, Secondary to choroidal neovascularization

1) Overview
FDA Approval: Adult, no; Pediatric, no
Efficacy: Adult, Evidence favors efficacy
Recommendation: Adult, Class IIb
Strength of Evidence: Adult, Category B
See your usual reference: RECOMMENDATION AND EVIDENCE RATINGS

2) Summary:
Administration of intravitreal bevacizumab has been associated with improved visual acuity (Bashshur et al, 2006; Spaide et al, 2006; Rich et al, 2006; Avery et al, 2006; Goff et al, 2007; Lazic et al, 2007), decreased central thickness (Bashshur et al, 2006; Spaide et al, 2006; Rich et al, 2006; Goff et al, 2007; Lazic et al, 2007), and decreased total macular volume (Lazic et al, 2007) in patients with choroidal neovascularization secondary to age-related macular degeneration.
There were no significant ocular side effects observed (Lazic et al, 2007; Lazic et al, 2007; Bashshur et al, 2006; Spaide et al, 2006; Rich et al, 2006; Avery et al, 2006); however, four occurrences of thromboembolic events were noted in one retrospective study (Spaide et al, 2006).

3) Adult:
a) Clinical Trials
1) Patients with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) treated with intravitreal bevacizumab experienced improved visual acuity and reduced retinal thickness in a retrospective study. Patients (n=51; mean age, 82 years (yr); range, 67-99 yr) with a baseline initial visual acuity of 20/320 (logMAR 1.2) or greater and subfoveal CNV from AMD received bevacizumab 1.25 mg intravitreally (injected through the pars plana into the vitreous cavity). Bevacizumab was given at one month intervals (in most cases) until there was no evidence of disease activity, although the schedule was determined by the treating physician. Photodynamic therapy with verteporfin (PDT) was allowed if the treating physician felt that treatment was failing to stabilize or improve vision or if there was evidence of persistent disease despite treatment. Additionally, some patients received topical antibiotics. Patients were evaluated initially by ophthalmic examinations using Early Treatment Diabetic Retinopathy Study (ET-DRS) charts, slit-lamp biomicroscopic examination of the anterior segment, and dilated fundoscopic examination of the posterior pole and then monthly with optical coherence tomography (OCT) (if possible) or fluorescein angiography and/or clinical examination. The mean duration of follow-up in this study was 138 days (range, 48-222 days) and there were 178 bevacizumab injections given to a total of 54 eyes (mean number of injections per eye, 3.3; range 1-7 injections). Overall, visual acuity was significantly improved (p=0.01) from an initial mean of 20/125 (logMAR 0.8) to a final mean of 20/100 (log MAR 0.7), with 46 of 54 eyes (85%) experiencing no change or improvement of at least one line of vision, 12 of 54 eyes (22%) experiencing an improvement of 3 or more lines of

Strength of efficacy and evidence ratings

Fully cited studies

Study detail

©2011 Thomson Reuters. All rights reserved. All other products names used herein are trademarks of their respective owners.
H PRO INTL 1109 10126



THOMSON REUTERS™